- Home
- AACT vs IMNM Comparison
AACT vs IMNM Comparison
Compare AACT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- IMNM
- Stock Information
- Founded
- AACT 2021
- IMNM 2006
- Country
- AACT United States
- IMNM United States
- Employees
- AACT N/A
- IMNM N/A
- Industry
- AACT
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- AACT
- IMNM Health Care
- Exchange
- AACT Nasdaq
- IMNM Nasdaq
- Market Cap
- AACT 677.5M
- IMNM 585.5M
- IPO Year
- AACT 2023
- IMNM 2020
- Fundamental
- Price
- AACT $11.00
- IMNM $10.17
- Analyst Decision
- AACT
- IMNM Strong Buy
- Analyst Count
- AACT 0
- IMNM 5
- Target Price
- AACT N/A
- IMNM $28.60
- AVG Volume (30 Days)
- AACT 75.8K
- IMNM 881.8K
- Earning Date
- AACT 01-01-0001
- IMNM 11-13-2024
- Dividend Yield
- AACT N/A
- IMNM N/A
- EPS Growth
- AACT 48.19
- IMNM N/A
- EPS
- AACT 0.43
- IMNM N/A
- Revenue
- AACT N/A
- IMNM $10,129,000.00
- Revenue This Year
- AACT N/A
- IMNM N/A
- Revenue Next Year
- AACT N/A
- IMNM N/A
- P/E Ratio
- AACT $25.56
- IMNM N/A
- Revenue Growth
- AACT N/A
- IMNM N/A
- 52 Week Low
- AACT $10.47
- IMNM $8.97
- 52 Week High
- AACT $11.02
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- AACT 65.98
- IMNM 43.50
- Support Level
- AACT $10.95
- IMNM $9.24
- Resistance Level
- AACT $11.00
- IMNM $10.52
- Average True Range (ATR)
- AACT 0.02
- IMNM 0.71
- MACD
- AACT 0.00
- IMNM 0.01
- Stochastic Oscillator
- AACT 71.43
- IMNM 43.22
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.